_id
690f39dcccc777a4e85d1905
Ticker
BVS
Name
Bioventus Inc
Exchange
NASDAQ
Address
4721 Emperor Boulevard, Durham, NC, United States, 27703
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://www.bioventus.com
Description
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Last Close
7.42
Volume
129293
Current Price
7.45
Change
0.4043126684636152
Last Updated
2025-11-29T11:02:09.830Z
Image
data:image/webp;base64,UklGRuQLAABXRUJQVlA4WAoAAAAQAAAAPwAAPwAAQUxQSFsHAAABoLZt2xlJXtL9vklj3LO2bdvmeG1rPLO2eta2bdu2be/YalXe97k+VJJGREyAOj/xkuQS7yQpderiqZf6rDPo5Marrx43fJcVvXzapXwird/4ZSQ//nJH/z5KXNdxTps9OX/WK5eNHnrOvb8Qo9H28u5eXdU5LXLLnw/stGBN99696tPF93qb2BaZf11P+S7hnPZ457KVFtzj5k/Hz2ya/dUVm/Yd3UQIxlvLynUBp/phd22wyqUTMIxJDw495JANNWAuROPLleU7zanv8KNWuWwuRmDelUvJqfowMzA+XFS+k5z69NvukD+wgDFpkFzivZeU3E6AwJ3Ouc5Rj3W2urNCxYAZOyvxyvVaazaGWTxcSSdpz6+oZIBxoLwKndLbyCDji6XlO855pyPmYmChjUvlVDLREIJBhaFyHeN8mjqnQ6ZN+X/yPCPw2RLy5db7jwiRzxeU64g0keTqVxx77MEHH3LC2be9/U8/1SeuhNfiHxKAyPYd4Z20xB6jbnzmvfc+/OijNx+/+eILTl9dkvdFTj2eI8tpVPudeg6++5vZlK789/1TY9aVJFeQPkoFMN5O2+Gcep70eQtGrFRCdZZVAoBNfvmYBeXkcro/S5YzYcFyXm7gt0AM0ShrFiIY/12yqpNP5LXouznQvGqpVEvckWFmdKSZAbOuWjNVmmqN3wk5cTO5okSbfkswOtHMmH7xikq1SwXLYfsSTnv+R6CTLUR+G9pLp1Ihf6sip12mk1HWrMrMSkEMcE+P1wl5besUeK33H4F8i5HyMVoRZNy3nkXLm7mkcr0aPiCQnxnQ9M9Xbz3z9Isf/TSxGbAsFkW2uJZAtfF9t7xElxItJwaY8sa5/ffa94gTTjhq/4H9Dr3inQkZlsWcwFMbNZNvPOxyEu0wg0h1jPwxbtNU288IVLf+erRq1xn58gxiZmDWtsn9FAaGKr/2fipUG02XriBXo2Npy7IsC8a9SqVuO14/iWhkjN4/FJiF9eVytmzCcvh2B6c0TXUIwQAzrlOS1DjVrHv5fCo8uu4fWF7g1V4F46gABN5YWj6REu2fB9wlL7nEK9ngUT5Y8UUCReeuUSMnaaFviUDGWwvJO0mp+hELHq2SnHeq67fWjWTkBz4Yfv8Ky8tJm2BA4IeVlag61U5t5Bhv5klKlF5LZnkWGHFbtukRVUcTwWgerBrlJtpiBjHvuxq5HK/6W4kUZrx10GQOGLmrEt1dFXlUiSta+8+i8UvkOS36EJFCY95JT8LF+92rxP2IYczdXanyvZb5nJA3ezN5yXmt+wHRytxxFoHnNv51XSV/5XzqvAqderxAllc5Uon38geOJzMKI5+eOI/ITyv+ea6SHzDgOiUlvG7Nw7hGdU5L3xUtUhyZNvJXojFl9We/aNCdROA4+SKlOoVoVZG3vRqO/A2jZIytoz/FMOZsciWb6rCqOFh1pQY1UfDvGpu9FomUjIExNY/nNG9/KmO0fjDDhiy0pnxBojV+J1YZ7H8VrZGSZtk5qRb9lmi07TiU53s2fECAUcsdkcjlOZe+Sagi4+b9mrASkdbRShP1q2rZYhjjl9FI2oyndN1gpYl3zidJrRqxnMjfO31KLDBj3uFKnFOvZ8iYu/Y5sL1W+JGMKQ37/ra5nHJrew6cjVWRMbyRwhj4dSc5JyU6jIwpS98AxyU6iWBcpHeaTlln4br6Rdfce9xvR3xcEPlxr/FYVRbjs8vLSVUbjoevG16CRqf6h6kwYc2NZjLxrceefOdvMi68iMKMMdcAWMas03vJq9pryU/gjiX/gzvktdQnVHi921FGbmzlu51nFRhT9vobA97cUqlXwYJvwYDtyHhA8lrpMwL3pidBpS2LRmDwg1gOkcePJzJlbIMSr6KlPuGfhmupVMlriWcIPNJzz/+xEA3jhZ2JecA5V3DvynJexYk2Hc/opWYRuUWSnGpPm2R8st6StzVhsRKx/g8Q8oy5w1eokZxKHclXfa/GImdXSU5r3TmJlgsX3+jGf4HIy9s1YzlEpg5STaKSTgu8Y+ttZxDZL09e2qTxK6ZcvsFqB97zawaXXU0lj8icUakSV2YMe6zxP2a0rVmgxMsttdsV3/791EnbbLDjcTfdsMPXhDxiqNy9tCTnqpwG/LT9Jn8SibzXu0hKvaQeaw4ZOeaI7ZdxvbRvM5ZHjPwxvEFOkpyWH7PZ0JlEqDBGpZ33qq7r1bu7lKiRaHlEg98u3HKhbrW19b22Oe0zzCAyYY1y1c45VTvnXPIg0fLAgPjPG489+vwPLWAGZFwo16529nmKYAWAUWgGkPH5UvKd4tTwBJmVAIshBCPXmLGTUnWuV8/rMsxKlDWj7RAl6myn5LBpmMX2RWPOwXKu0+S8VnusFUIWrchiCMY3W0tOXdA5qd/LczFCJYQYQ1YJEP8Z11dOXdR51e98wxfzKDn7/fNXkXfqut5LS+42+qYXvx4//psXbxyx40KSd+rSaSLJ9Vlm9dWX7eMlpYm6uvNp4pSfJF5lAQBWUDggYgQAANAUAJ0BKkAAQAA+pUKbSaYjoqEz+A6owBSJbAC++Y3VfAbVv/J/zzdYDc29f7t6sNs95gPOK9DnnHdQj6AHSW/u/6XNNJmsbwbqtMUVJtpuoR0Yv3O9mN20QCxtY6utf9Z8QplYDrNX69dks+JFDITpbsqQ7EAEE7671kdW4evjmfIgTLm/f2w6ndl4IkRxBg7YpxVTvRaIfjJlh77K2jdUEcHJwZ4/SOvCa+bOYAAA/v85vV+Ol8b1jPDgfP6BclU5/Y8xgJhwmk2jfi8kRriNY/eSiOkDpyJv3/wLmzeoAk9dJ0aMBwIpMRCafQisP95TD3XYVeN+YNPHZ8laooVrbGGXuljBl+jzAYga51HrHG4yEzQfycYwbB/jnWhsV7aSK/FR1LmJGqPDK+tUMTtow+k2TuoLbGG0Pd0NehYyOIPDl0ni8oMZQAqOf1moUFB4LvHMK2Gn2YBW3T+h6RM4+J4fVk+/5g61sq0t9Mz3B21LzvwKrbQy75s3UVD6zJzyfqh5/WVp+LKySeGYy2biYf9Lh6YHxvOGHagFxqjrkBr4mPhdKZvuRnXf5G89q7ZrI86CRebsLl8NwcirB7dwgAw5ruIu57r7PtPlyKQyLpZRBooQwQbsAJMRMQa2PCrEHyaTctIv9xIGyxhqPjQzzdHxrqu4rZ53TkZ1c6CL91ChsOAord6TL0CHdB4OO216NLKiKdcQvRYLMB5IO2IDh/FgE08gxeJr8QI/10VUvrUFiB71vE3RTdyBaxubsp4we1homcCwUEZLmEJoqtJNRUdPY94O5SWBarKvkuPRoVDY9CcbYrt+IisQa+84XF5ivrS/cGww1VjEwhpWKeWNRSe94SwWPZ9YbSsIpciruptjRdG4eRKCnzhv5+vwssultoVJfl5tCpHwb4k+CvlAliOwRSysOrg7546j2J+bOcZHjSrLA7nHw+ehqYp3KUrxXxeiXj2mX5hCCEDD45Kemf05pAymUhEgjGWe1A/ZzW5kkxMjQVZMl7jQYAWVrC51AAQ/H7l6ebj/W5PGwy1SiHBV3TaGIdpVvnZ8KEqvL7NmDuVj7cWGbrfPex7lL/PCp9pvAYpApPm+ppRRDwfxA+luBQKpPe/a48AbpGvsbNzLCtZTAl71+Ciav/tj1NqfZ0DMjxI7vQpfLNRN9+MeR4xgpKcLb2c9sI5IXpwjfiVaMifIIVZK3kvUxuNGdz+wd/2O+hS+5SV79RR1hqpG48b+OCL2NovHmdsWNnaDezwodJ5BTNJwgFxMEr5maf3zs72YR0vjib3qZGk8IG1htPpve4uIGV+IvZ1f3MXdV47iEOPQow+J+0a7wjREl0wfg4/DDlNDiUSxS+zvYYMRoXlyqBZlZo3kK1uljusACjOBZv7sreuPjcpNw+1Tz5bLBE6Qmp16VOR9jQLLEPXQlB3BQFn8olwR1Ogyim8OrojDvrlbM1qN3epapBe6ut4zCXMgtVFNAPqMI+u5+gAAAA==
Ipo Date
2021-02-11T00:00:00.000Z
Market Cap
508351456
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9902
Sentiment Sources
5
Rating
4.3333
Target Price
15
Strong Buy
2
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
138651000
Cost Of Revenue
45820000
Gross Profit
92831000
Operating Expenses
80727000
Operating Income
12104000
Interest Expense
6177000
Pretax Income
4670000
Net Income
3155000
Eps
0.04583237897633476
Dividends Per Share
-
Shares Outstanding
66976477
Income Tax Expense
664000
EBITDA
22250000
Operating Margin
8.729832457032405
Total Other Income Expense Net
-7434000
Cash
42164000
Short Term Investments
-
Receivables
130404000
Inventories
96273000
Total Current Assets
280901000
Property Plant Equipment
28813000
Total Assets
701593000
Payables
26649000
Short Term Debt
15657000
Long Term Debt
311334000
Total Liabilities
494338000
Equity
166096000
Depreciation
11403000
Change In Working Capital
10677000
Cash From Operations
30098000
Capital Expenditures
473000
Cash From Investing
-473000
Cash From Financing
-19977000
Net Change In Cash
9254001
PE
47.4375
PB
3.0876215420600137
ROE
1.8995039013582504
ROA
0.4496909176687909
FCF
29625000
Fcf Percent
0.21366596706839475
Piotroski FScore
4
Health Score
52
Deep Value Investing Score
4
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
2.5
Growth Investing Score
3
Momentum Investing Score
6
Net Net Investing Score
2.5
Quality Investing Score
3.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
138651000
Quarters > 0 > income Statement > cost Of Revenue
45820000
Quarters > 0 > income Statement > gross Profit
92831000
Quarters > 0 > income Statement > operating Expenses
80727000
Quarters > 0 > income Statement > operating Income
12104000
Quarters > 0 > income Statement > interest Expense
6177000
Quarters > 0 > income Statement > pretax Income
4670000
Quarters > 0 > income Statement > net Income
3155000
Quarters > 0 > income Statement > eps
0.04583237897633476
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
68837797
Quarters > 0 > income Statement > income Tax Expense
664000
Quarters > 0 > income Statement > EBITDA
22250000
Quarters > 0 > income Statement > operating Margin
8.729832457032405
Quarters > 0 > income Statement > total Other Income Expense Net
-7434000
Quarters > 0 > balance Sheet > cash
42164000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
130404000
Quarters > 0 > balance Sheet > inventories
96273000
Quarters > 0 > balance Sheet > total Current Assets
280901000
Quarters > 0 > balance Sheet > property Plant Equipment
28813000
Quarters > 0 > balance Sheet > total Assets
701593000
Quarters > 0 > balance Sheet > payables
26649000
Quarters > 0 > balance Sheet > short Term Debt
15657000
Quarters > 0 > balance Sheet > long Term Debt
311334000
Quarters > 0 > balance Sheet > total Liabilities
494338000
Quarters > 0 > balance Sheet > equity
166096000
Quarters > 0 > cash Flow > net Income
3155000
Quarters > 0 > cash Flow > depreciation
11403000
Quarters > 0 > cash Flow > change In Working Capital
10677000
Quarters > 0 > cash Flow > cash From Operations
30098000
Quarters > 0 > cash Flow > capital Expenditures
473000
Quarters > 0 > cash Flow > cash From Investing
-473000
Quarters > 0 > cash Flow > cash From Financing
-19977000
Quarters > 0 > cash Flow > net Change In Cash
9254001
Quarters > 0 > ratios > PE
0.04583237897633476
Quarters > 0 > ratios > PB
3.0876215420600137
Quarters > 0 > ratios > ROE
1.8995039013582504
Quarters > 0 > ratios > ROA
0.4496909176687909
Quarters > 0 > ratios > FCF
29625000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.21366596706839475
Quarters > 0 > health Score
52
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
147660000
Quarters > 1 > income Statement > cost Of Revenue
45570000
Quarters > 1 > income Statement > gross Profit
102090000
Quarters > 1 > income Statement > operating Expenses
83722000
Quarters > 1 > income Statement > operating Income
18368000
Quarters > 1 > income Statement > interest Expense
7494000
Quarters > 1 > income Statement > pretax Income
10313000
Quarters > 1 > income Statement > net Income
7459000
Quarters > 1 > income Statement > eps
0.1088321086207184
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
68536759
Quarters > 1 > income Statement > income Tax Expense
1041000
Quarters > 1 > income Statement > EBITDA
29856000
Quarters > 1 > income Statement > operating Margin
12.439387782744141
Quarters > 1 > income Statement > total Other Income Expense Net
-8055000
Quarters > 1 > balance Sheet > cash
32910000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
132367000
Quarters > 1 > balance Sheet > inventories
96465000
Quarters > 1 > balance Sheet > total Current Assets
275203000
Quarters > 1 > balance Sheet > property Plant Equipment
30737000
Quarters > 1 > balance Sheet > total Assets
706788000
Quarters > 1 > balance Sheet > payables
24245000
Quarters > 1 > balance Sheet > short Term Debt
43358000
Quarters > 1 > balance Sheet > long Term Debt
297880000
Quarters > 1 > balance Sheet > total Liabilities
505489000
Quarters > 1 > balance Sheet > equity
161242000
Quarters > 1 > cash Flow > net Income
9272000
Quarters > 1 > cash Flow > depreciation
12049000
Quarters > 1 > cash Flow > change In Working Capital
477000
Quarters > 1 > cash Flow > cash From Operations
25938000
Quarters > 1 > cash Flow > capital Expenditures
683000
Quarters > 1 > cash Flow > cash From Investing
-1369000
Quarters > 1 > cash Flow > cash From Financing
-14663000
Quarters > 1 > cash Flow > net Change In Cash
10108000
Quarters > 1 > ratios > PE
0.1088321086207184
Quarters > 1 > ratios > PB
3.1666616300343584
Quarters > 1 > ratios > ROE
4.625965939395442
Quarters > 1 > ratios > ROA
1.0553376684380606
Quarters > 1 > ratios > FCF
25255000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.17103480969795476
Quarters > 1 > health Score
48
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
123876000
Quarters > 2 > income Statement > cost Of Revenue
40820000
Quarters > 2 > income Statement > gross Profit
83056000
Quarters > 2 > income Statement > operating Expenses
78187000
Quarters > 2 > income Statement > operating Income
4869000
Quarters > 2 > income Statement > interest Expense
7509000
Quarters > 2 > income Statement > pretax Income
-3417000
Quarters > 2 > income Statement > net Income
-2637000
Quarters > 2 > income Statement > eps
-0.0399492897017806
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
66008683
Quarters > 2 > income Statement > income Tax Expense
-95000
Quarters > 2 > income Statement > EBITDA
15957000
Quarters > 2 > income Statement > operating Margin
3.930543446672479
Quarters > 2 > income Statement > total Other Income Expense Net
-8286000
Quarters > 2 > balance Sheet > cash
22802000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
118082000
Quarters > 2 > balance Sheet > inventories
94045000
Quarters > 2 > balance Sheet > total Current Assets
249367000
Quarters > 2 > balance Sheet > property Plant Equipment
32353000
Quarters > 2 > balance Sheet > total Assets
691414000
Quarters > 2 > balance Sheet > payables
19197000
Quarters > 2 > balance Sheet > short Term Debt
37339000
Quarters > 2 > balance Sheet > long Term Debt
308593000
Quarters > 2 > balance Sheet > total Liabilities
505935000
Quarters > 2 > balance Sheet > equity
148144000
Quarters > 2 > cash Flow > net Income
-3322000
Quarters > 2 > cash Flow > depreciation
11865000
Quarters > 2 > cash Flow > change In Working Capital
-31201000
Quarters > 2 > cash Flow > cash From Operations
-19331000
Quarters > 2 > cash Flow > capital Expenditures
826000
Quarters > 2 > cash Flow > cash From Investing
-826000
Quarters > 2 > cash Flow > cash From Financing
947000
Quarters > 2 > cash Flow > net Change In Cash
-18780000
Quarters > 2 > ratios > PE
-0.0399492897017806
Quarters > 2 > ratios > PB
3.3195045924910898
Quarters > 2 > ratios > ROE
-1.7800248406955395
Quarters > 2 > ratios > ROA
-0.38139233512772375
Quarters > 2 > ratios > FCF
-20157000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-0.16271917078368692
Quarters > 2 > health Score
11
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
153642000
Quarters > 3 > income Statement > cost Of Revenue
50986000
Quarters > 3 > income Statement > gross Profit
102656000
Quarters > 3 > income Statement > operating Expenses
94668000
Quarters > 3 > income Statement > operating Income
7988000
Quarters > 3 > income Statement > interest Expense
8997000
Quarters > 3 > income Statement > pretax Income
232000
Quarters > 3 > income Statement > net Income
-156000
Quarters > 3 > income Statement > eps
-0.002383430355500402
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
65451881
Quarters > 3 > income Statement > income Tax Expense
550000
Quarters > 3 > income Statement > EBITDA
21634000
Quarters > 3 > income Statement > operating Margin
5.199099204644563
Quarters > 3 > income Statement > total Other Income Expense Net
-7756000
Quarters > 3 > balance Sheet > cash
41582000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
127393000
Quarters > 3 > balance Sheet > inventories
92475000
Quarters > 3 > balance Sheet > total Current Assets
275610000
Quarters > 3 > balance Sheet > property Plant Equipment
33518000
Quarters > 3 > balance Sheet > total Assets
727956000
Quarters > 3 > balance Sheet > payables
23690000
Quarters > 3 > balance Sheet > short Term Debt
27339000
Quarters > 3 > balance Sheet > long Term Debt
308288000
Quarters > 3 > balance Sheet > total Liabilities
542352000
Quarters > 3 > balance Sheet > equity
147940000
Quarters > 3 > cash Flow > net Income
-318000
Quarters > 3 > cash Flow > depreciation
12405000
Quarters > 3 > cash Flow > change In Working Capital
-2108000
Quarters > 3 > cash Flow > cash From Operations
19322000
Quarters > 3 > cash Flow > capital Expenditures
574000
Quarters > 3 > cash Flow > cash From Investing
24104000
Quarters > 3 > cash Flow > cash From Financing
-42855000
Quarters > 3 > cash Flow > net Change In Cash
-1492000
Quarters > 3 > ratios > PE
-0.002383430355500402
Quarters > 3 > ratios > PB
3.2960424053670407
Quarters > 3 > ratios > ROE
-0.1054481546572935
Quarters > 3 > ratios > ROA
-0.021429866640291447
Quarters > 3 > ratios > FCF
18748000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.12202392574946955
Quarters > 3 > health Score
23
Valuation > metrics > PE
47.4375
Valuation > metrics > PB
3.0876215420600137
Valuation > final Score
22.198784579399867
Valuation > verdict
46.3% Overvalued
Profitability > metrics > ROE
1.8995039013582504
Profitability > metrics > ROA
1.1231715088233933
Profitability > metrics > Net Margin
0.022754974720701617
Profitability > final Score
11
Profitability > verdict
Weak
Risk > metrics > Debt Equity
2.9762185723918697
Risk > metrics > Interest Coverage
1.959527278614214
Risk > final Score
26
Risk > verdict
High
Liquidity > metrics > Current Ratio
6.639743771569044
Liquidity > metrics > Quick Ratio
4.364109109818938
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
68.33338369965642
Prev Valuations > 1
46.8049540750891
Prev Valuations > 2
47.03957594632959
Prev Profitabilities > 0
25
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
16
Prev Risks > 1
9
Prev Risks > 2
10
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T00:30:04.819Z
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABravura Solutions (ASX:BVS) jumps 6.7% this week, though earnings growth is still tracking behind three-year shareholder returns simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$15
Analyst Picks
Strong Buy
2
Buy
0
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 75.32% of the total shares of Bioventus Inc
1.
Essex Woodlands Health Ventures(19.4661%)
since
2025/06/30
2.
Juniper Investment Co, LLC(10.3739%)
since
2025/06/30
3.
Nantahala Capital Management, LLC(7.8945%)
since
2025/06/30
4.
BlackRock Inc(4.6891%)
since
2025/06/30
5.
Vanguard Group Inc(4.1889%)
since
2025/06/30
6.
iShares Russell 2000 ETF(1.697%)
since
2025/08/31
7.
American Century Companies Inc(1.6804%)
since
2025/06/30
8.
Royce & Associates, LP(1.6326%)
since
2025/06/30
9.
Divisadero Street Capital Management, LP(1.6155%)
since
2025/06/30
10.
Geode Capital Management, LLC(1.577%)
since
2025/06/30
11.
Vanguard Total Stock Mkt Idx Inv(1.5087%)
since
2025/07/31
12.
Avantis US Small Cap Value ETF(1.4367%)
since
2025/08/30
13.
State Street Corp(1.3217%)
since
2025/06/30
14.
Renaissance Technologies Corp(1.1822%)
since
2025/06/30
15.
Dimensional Fund Advisors, Inc.(1.0043%)
since
2025/06/30
16.
Morgan Stanley - Brokerage Accounts(0.9761%)
since
2025/06/30
17.
Millennium Management LLC(0.906%)
since
2025/06/30
18.
Oberweis Asset Management Inc(0.8995%)
since
2025/06/30
19.
Oberweis Micro-Cap Growth(0.8995%)
since
2025/06/30
20.
Oberweis Micro-Cap(0.8995%)
since
2025/06/30
21.
Royce Small-Cap Opportunity Invmt(0.8833%)
since
2025/06/30
22.
FTGF RY US SmCp Opp A USD Dis(A)(0.7639%)
since
2025/08/31
23.
Vanguard Institutional Extnd Mkt Idx Tr(0.6929%)
since
2025/07/31
24.
Fidelity Small Cap Index(0.6906%)
since
2025/06/30
25.
Charles Schwab Investment Management Inc(0.6278%)
since
2025/06/30
26.
Qube Research & Technologies(0.6258%)
since
2025/06/30
27.
iShares Russell 2000 Growth ETF(0.6218%)
since
2025/08/31
28.
Northern Trust Corp(0.5893%)
since
2025/06/30
29.
AQR Capital Management LLC(0.5819%)
since
2025/06/30
30.
Kent Lake PR LLC(0.5233%)
since
2025/06/30
31.
Knights of Columbus Small Cap I(0.4004%)
since
2025/07/31
32.
Fidelity Enhanced Small Cap ETF(0.3495%)
since
2025/08/29
33.
Fidelity Extended Market Index(0.3423%)
since
2025/07/31
34.
Vanguard Russell 2000 ETF(0.3296%)
since
2025/07/31
35.
Schwab US Small-Cap ETFâ„¢(0.3055%)
since
2025/08/30
36.
US Equity Small Cap Corporate Cl OF(0.2622%)
since
2024/12/31
37.
US Equity Small Cap Pool A(0.2359%)
since
2024/12/31
38.
Vanguard VIF Small Co Gr(0.227%)
since
2025/06/30
39.
Vanguard Explorer Inv(0.2098%)
since
2025/06/30
40.
DFA US Small Cap I(0.2094%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.